Warning letter
Irenda Corporation: warning letter of Apr 15, 2013
FDA warning letter 378178 · Los Angeles District Office
Key facts
| Reference number | 378178 |
|---|---|
| Company | Irenda Corporation |
| Subject | CGMP/Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements/Adulterated |
| Issue date | Apr 15, 2013 |
| Posted date | Apr 15, 2013 |
| Issuing office | Los Angeles District Office |
| Product type | Food/Cosmetics |
| CFR sections cited | 111.75(a)(2), 111, 111.15(a)(1), 111.15(b)(2), 111.35(b)(3), 111.70(b), 111.75(a)(2)(ii), 111.455(c), 111.75(a), 111.75(a)(1)(i), 111.75(a)(1)(ii), 111.75(c)(1) |
| Inspection city | Los Angeles |
| Inspection ZIP | 90061 |
| Inspection start date | Sep 12, 2012 |
| Letter on fda.gov | web.archive.org |
At a glance
- 10–99 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: